| Description |
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition[1].
|
| Related Catalog |
|
| Target |
VEGF; EGFL7[1]
|
| In Vitro |
EGFL7 is a vascular-restricted extracellular matrix protein that promotes endothelial cell adhesion and survival[1]. Parsatuzumab (48 h) inhibits cell proliferation and increases apoptosis against patient-derived xenograft (PDX) cells[2]. Cell Viability Assay[2] Cell Line: Patient-derived xenograft (PDX) cells Concentration: / Incubation Time: 48 hours Result: Inhibited cell proliferation by 70% from 20%, and resulted in apoptosis increases by 67-87% from 8-17%.
|
| In Vivo |
Parsatuzumab (anti-EGFL7) enhances the antiangiogenesis, tumor growth control, and survival associated with antiVEGF monotherapy in several xenograft and genetically engineered murine tumor models[1]. Parsatuzumab (50 mg/kg; i.v.; 3 times per week) targets EGFL7 and inhibits mantle cell lymphoma (MCL) cell growth and prolongs survival in mouse models of MCL[2]. Animal Model: NSG mice injected with Rec1 cells (s.c.)[2] Dosage: 50 mg/kg Administration: Intravenous injection; 3 times per week; sacrificed mice when tumor reached end point criteria Result: Significantly decreased tumor volume than IgG and increased survival of mice.
|
